TWD 68.7
(0.15%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | 84.69 Million TWD | 47.34% |
2022 | 74.04 Million TWD | 76.7% |
2021 | 41.9 Million TWD | 453.95% |
2020 | 7.56 Million TWD | -7.63% |
2019 | 8.18 Million TWD | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q1 | 33.21 Million TWD | 337.5% |
2024 Q2 | 26.07 Million TWD | -48.58% |
2023 Q4 | 7.59 Million TWD | -67.22% |
2023 FY | 109.09 Million TWD | 47.34% |
2023 Q3 | 23.16 Million TWD | -47.42% |
2023 Q2 | 44.04 Million TWD | 28.41% |
2023 Q1 | 34.3 Million TWD | 124.87% |
2022 FY | 74.04 Million TWD | 76.7% |
2022 Q4 | 15.25 Million TWD | 0.0% |
2021 FY | 41.9 Million TWD | 453.95% |
2020 FY | 7.56 Million TWD | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
DIVA Laboratories, Ltd. | 92.15 Million TWD | 8.094% |
Genetics Generation Advancement Corp. | 18.57 Million TWD | -355.927% |
Welgene Biotech Co.,Ltd. | -4.25 Million TWD | 2088.565% |
Puriblood Medical Co., Ltd. | -50.4 Million TWD | 268.032% |
TFBS Bioscience Inc. | -4.45 Million TWD | 2001.931% |